Rationale Development of Combination Cancer Immunotherapy through Collaborations

ASCPT 2016
San Diego, CA
March 12, 2016

Co-Chairs:
Eric Masson, AstraZeneca
Paul Statkevich, Bristol-Myers Squibb
Combination Cancer Immunotherapy

Figure 3 | Schematic representation of the main mechanisms of action postulated to mediate synergistic effects of combined immunotherapies.

Rationale Development of Combination Cancer Immunotherapy through Collaborations

Agenda:

• Role of Translational Science in Immuno-Oncology Combination Development
  • John Kurland, Ph.D., MedImmune

• Quantitative Clinical Pharmacology for Early Decision Making During Combination Immunotherapy Development
  • Shruti Agrawal, Ph.D., Bristol-Myers Squibb

• Regulatory Considerations for Immuno-Oncology Combination Drug Development
  • Atiqr Rahman, Ph.D., US Food and Drug Administration
Workshop Objectives:

1) Highlight the current challenges in development of immunotherapy in combination with other treatment modalities in oncology such as combination selection based on biomarker strategies, clinical trial design, initial dosing scenarios, evaluation of safety and efficacy, and potential solutions for overcoming challenges and faster clinical development.

2) Describe case studies where immune check point inhibitors in combination have resulted in benefit to patients in terms of response and elaborate challenges and issue resolution in combination drug development, integrated quantitative exposure-response analyses of combination immunotherapy, and analysis to guide decision making.

3) Review the regulatory perspective on challenges in translational and clinical development of combination immunotherapy